Montelucaste Sandoz (Montelukast)

Montelukast, the active ingredient in Montelucaste Sandoz, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used for maintenance therapy of asthma, relief of allergic rhinitis symptoms, and prevention of exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelucaste Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene receptor antagonist that addresses inflammatory airway conditions. - Asthma (maintenance therapy): reduces frequency and severity of asthma attacks and improves overall lung function. - Allergic rhinitis: alleviates nasal congestion, sneezing, and itchy watery eyes caused by seasonal or perennial allergens. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during physical activity, allowing better exercise tolerance.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often reported. - Abdominal pain: discomfort or cramping in the stomach area. - Cough: occasional dry or productive cough. - Sore throat: irritation or pain in the throat. - Nausea: feeling of queasiness or urge to vomit. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Mood changes: depression, anxiety, or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Bronchospasm: paradoxical worsening of breathing. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Montelucaste Sandoz, consider the following safety measures. - Pregnancy: consult a healthcare professional before use; benefits must outweigh potential risks. - Liver disease: monitor hepatic function as metabolism occurs in the liver. - Concomitant CYP3A4 inhibitors: may increase drug exposure; dose adjustment may be needed. - Not for acute asthma attacks: use a short‑acting bronchodilator for rescue. - Age considerations: safety established in children aged 12 months and older; follow pediatric guidance. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Montelukast may interact with other medicines; awareness of interaction severity helps guide monitoring.

Major Interactions (Avoid): - Ritonavir: potent CYP3A4 inhibitor that can markedly increase montelukast plasma levels. - Phenobarbital: strong enzyme inducer that may reduce therapeutic effectiveness.

Moderate Interactions (Monitor Closely): - Fluconazole: moderate CYP3A4 inhibition may raise montelukast concentrations. - Carbamazepine: enzyme induction can lower drug exposure. - Warfarin: possible effect on anticoagulation; monitor INR when co‑administered.